Ganymed Pharmaceuticals Ag

Johannes Gutenberg-Universität Mainz

Astellas Pharma Gmbh

Ganymed Pharmaceuticals Gmbh

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Tron—translationale Onkologie An Der Universitat

Johannes Gutenberg-universität Mainz, Vertreten Durch Den Präsidenten

Christoph Uherek

Ugur Sahin

Dirk Usener

Harald-Gerhard Geppert

Stefan Fritz

Gunda Brandenburg

Phillippe Thiel

Özlem Türeci

Anja Kristina Schröder

Ozlem Tureci

Philippe Thiel

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

Monoclonal antibodies against Claudin-18 for treatment of cancer

Monoclonal antibodies against claudin-18 for treatment of cancer

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

Growing community of inventors

Ginsheim, Germany

Christoph Uherek